Literature DB >> 16394702

Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms.

J A Jeevendra Martyn1, Martina Richtsfeld.   

Abstract

Lethal hyperkalemic response to succinylcholine continues to be reported, but the molecular mechanisms for the hyperkalemia have not been completely elucidated. In the normal innervated mature muscle, the acetylcholine receptors (AChRs) are located only in the junctional area. In certain pathologic states, including upper or lower motor denervation, chemical denervation by muscle relaxants, drugs, or toxins, immobilization, infection, direct muscle trauma, muscle tumor, or muscle inflammation, and/or burn injury, there is up-regulation (increase) of AChRs spreading throughout the muscle membrane, with the additional expression of two new isoforms of AChRs. The depolarization of these AChRs that are spread throughout the muscle membrane by succinylcholine and its metabolites leads to potassium efflux from the muscle, leading to hyperkalemia. The nicotinic (neuronal) alpha7 acetylcholine receptors, recently described to be expressed in muscle also, can be depolarized not only by acetylcholine and succinylcholine but also by choline, persistently, and possibly play a critical role in the hyperkalemic response to succinylcholine in patients with up-regulated AChRs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16394702     DOI: 10.1097/00000542-200601000-00022

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  41 in total

1.  Potency of nondepolarizing muscle relaxants on muscle-type acetylcholine receptors in denervated mouse skeletal muscle.

Authors:  Hong WANG; Bin YANG; Guang-wei HAN; Shi-tong LI
Journal:  Acta Pharmacol Sin       Date:  2010-11-22       Impact factor: 6.150

Review 2.  Pathogenesis, diagnosis and management of hyperkalemia.

Authors:  Anja Lehnhardt; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

3.  A single injection of botulinum toxin decreases the margin of safety of neurotransmission at local and distant sites.

Authors:  Christiane G Frick; Heidrun Fink; Manfred Blobner; Jeevendra Martyn
Journal:  Anesth Analg       Date:  2011-10-14       Impact factor: 5.108

4.  Early acute management in adults with spinal cord injury: a clinical practice guideline for health-care professionals.

Authors: 
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

5.  Immobilization with atrophy induces de novo expression of neuronal nicotinic α7 acetylcholine receptors in muscle contributing to neurotransmission.

Authors:  Sangseok Lee; Hong-Seuk Yang; Tomoki Sasakawa; Mohammed A S Khan; Ashok Khatri; Masao Kaneki; J A Jeevendra Martyn
Journal:  Anesthesiology       Date:  2014-01       Impact factor: 7.892

Review 6.  Rocuronium versus succinylcholine for rapid sequence induction intubation.

Authors:  Diem T T Tran; Ethan K Newton; Victoria A H Mount; Jacques S Lee; George A Wells; Jeffrey J Perry
Journal:  Cochrane Database Syst Rev       Date:  2015-10-29

7.  Emergency Neurological Life Support: Airway, Ventilation, and Sedation.

Authors:  Venkatakrishna Rajajee; Becky Riggs; David B Seder
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

Review 8.  Acute and perioperative care of the burn-injured patient.

Authors:  Edward A Bittner; Erik Shank; Lee Woodson; J A Jeevendra Martyn
Journal:  Anesthesiology       Date:  2015-02       Impact factor: 7.892

Review 9.  Dyskalaemia following diffuse axonal injury: case report and review of the literature.

Authors:  David Cronin; Chandrasekaran Kaliaperumal; Ramanathan Kumar; George Kaar
Journal:  BMJ Case Rep       Date:  2012-10-10

10.  Chronic Escherichia coli infection induces muscle wasting without changing acetylcholine receptor numbers.

Authors:  Christiane G Frick; Heidrun Fink; Maria L Gordan; Barbara Eckel; J A Jeevendra Martyn; Manfred Blobner
Journal:  Intensive Care Med       Date:  2007-10-20       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.